Jaguar Health, Inc. (JAGX) Earnings Call Transcript & Summary
April 10, 2026
What were the key takeaways from Jaguar Health, Inc.'s April 10, 2026 earnings call?
In the fourth quarter of 2025, Jaguar Health, Inc. (JAGX:US) reported a revenue of approximately $3.2 million, reflecting a 5% increase from the previous quarter but an 8% decline year-over-year. The company experienced a significant operational loss of $45.9 million for the fiscal year 2025, up from $30.8 million in 2024. Management highlighted a transformative licensing agreement with Future Pak, which provides $18 million in upfront payments, aimed at focusing development on rare-disease intestinal failure indications, signaling a strategic pivot that could enhance future growth prospects.
What topics did Jaguar Health, Inc. cover?
- Licensing Agreement with Future Pak: Jaguar finalized a U.S. out-license agreement with Future Pak for Mytesi, bringing in $18 million upfront, of which $16 million has already been received. This deal allows Jaguar to focus on rare-disease indications while Future Pak manages commercial efforts, marking a strategic shift for the company.
- Revenue Performance: Total net revenue for Q4 2025 was approximately $3.2 million, a 5% increase from Q3 2025 but an 8% decrease compared to Q4 2024. This indicates a mixed performance as the company transitions its business model.
- Operational Loss Increase: Jaguar reported a significant increase in operational loss, which rose to $45.9 million in 2025 from $30.8 million in 2024. This raises concerns about the company's cost management amid its strategic transition.
- Focus on Rare-Disease Pipeline: Management emphasized a strategic focus on developing crofelemer for rare-disease intestinal failure indications, particularly targeting MVID and short bowel syndrome. The potential market for these indications is estimated to be significantly larger than the current Mytesi market.
- Clinical Development Milestones: Jaguar is in late-stage clinical development for its rare-disease programs, with a target for a New Drug Application for MVID in 2027. Management indicated that the upcoming milestones could be transformative for the company and its stakeholders.
What were Jaguar Health, Inc.'s April 10, 2026 results?
- Total Revenue: $3.2 million (vs $3.1 million in Q3 2025, +5% QoQ; vs $3.5 million in Q4 2024, -8% YoY)
- Operational Loss: $45.9 million (increased from $30.8 million in 2024)
- Net Loss Attributable to Common Shareholders: $53.6 million (up from $38.5 million in 2024)
- Mytesi Prescription Volume Change: -12.2% (in Q4 2025 vs Q4 2024)
- Upfront Payment from Future Pak: $18 million (includes $16 million received and $2 million contingent)
- Market Opportunity for Short Bowel Syndrome: $8 billion (projected market size by 2023)
Jaguar Health is at a pivotal moment with its strategic shift towards rare-disease indications and the recent licensing agreement with Future Pak. While the upfront payment provides immediate financial relief, the company must address declining prescription volumes and increasing losses. Investors should monitor upcoming clinical milestones and the company's ability to secure further partnerships as potential catalysts for stock movement.
Earnings Call Speaker Segments
Thank you so much, Melissa, and thanks to everyone. Hi there. I appreciate your participation in the Investor Webcast today. As was mentioned, I'm Lisa Conte. I serve as Founder, President, and CEO of Jaguar Health, along with our fully-owned subsidiary Napo Pharmaceuticals, and I hold the Chairman position at our Italian subsidiary, Napo Therapeutics. So, as is typical, I might refer to the Company using Jaguar and Napo as interchangeable terms. Following my remarks, Carol Lizak, our CFO, will give a summary of financial highlights from the fourth quarter of 2025, which was last year. I'm pleased to get out in front of Carol's news once more, and I'm equally delighted to report that our net revenue overall for the fourth quarter of 2025 reached approximately $3.2 million, combining prescription products, nonprescription products, and licensing income — a gain of roughly 5% over the roughly $3.1 million in net revenue we posted in the third quarter of 2025. Our attention in 2026 is fixed on business development, and I'm pleased to characterize that effort as continuous business development. "What's Different Now" serves as our theme. To start, I'd like to explain how we built a business platform at Jaguar that is truly transformative. The turning point arrived when we signed the final U.S. out-license deal with Future Pak for Mytesi, our FDA-approved crofelemer tablet formulation — Mytesi — a deal that perfectly matches our approach of concentrating crofelemer development sharply on rare-disease intestinal failure indications. That out-license arrangement also includes Canalevia-CA1, which is crofelemer for treating chemotherapy-induced diarrhea in dogs, under conditional approval. The main transformative aspects of this transaction are clear. To start, non-dilutive funds give us the resources needed to advance our rare-disease pipeline. There was $18 million upfront in the deal, and we've already gotten $16 million of that. We received $2 million upon signing in January, with another $2 million contingent on specific conditions, plus $20 million more in milestone and other future payments. The money we've brought in doesn't dilute shareholder value, and on top of that $16 million, we've already received close to $4 million in further payments — again, none of this dilutes existing shares. For a number of years, this is what we've envisioned, what we've pursued, and what we've aimed toward. Jaguar continues to produce crofelemer, which we provide to Future Pak at a gain, so that arrangement has become a source of profit. We hold what is genuinely groundbreaking data concerning rare disease, which I'll get into soon, together with short-term catalysts on the development, clinical, and regulatory fronts for an illness whose natural course is fatal, and with endpoints we are studying in hopes of possibly extending survival in that context. Our rare-disease intestinal failure initiative has reached the late stages of clinical development. This program covers microvillus inclusion disease, or MVID, which is an extremely uncommon congenital diarrheal condition, along with short bowel syndrome accompanied by intestinal failure. Regarding MVID, we are targeting a New Drug Application submission in 2027, the same year we expect to wrap up a Phase II placebo-controlled study in short bowel syndrome. As for short bowel syndrome, analysts outside the company have put the market opportunity at about $8 billion by 2023. That number is roughly 100 times bigger than the projected market size for Mytesi in HIV. Under that arrangement, we collected an upfront payment totaling $18 million. That should give you a picture of just how massive this is and what a blockbuster opportunity we have when it comes to how it affects patients, how it affects mortality and morbidity, and what it costs the health care system. And as we look to add more partnerships — the kind of non-dilutive dollars we want to bring into this Company — we have genuinely meaningful catalysts coming up over the next 6 to 12 months, which you'll hear about as I keep moving through this presentation, along with a goal of licensing — securing a license deal for rare disease. That's the Company's key objective and, as I said, that's our strategy for 2026. We do have a slide that summarizes these points, Carol, I'm not sure if you are able to put that slide up. Terrific. Terrific. As I mentioned, the intestinal-failure program is a blockbuster market, and it's catastrophic for the patients. What is intestinal failure? Intestinal failure is a situation where the patient can't absorb their nutrients of life. Their proteins, their carbs, vitamins, et cetera. So they end up on parenteral nutrition, parenteral support, that's IV support up to 20 hours a day, 7 days a week; so, obviously, hugely catastrophic for quality-of-life, but also for other health issues. This is TPN, or parenteral support. But patients frequently view Total Parenteral Nutrition as being about as poisonous as chemo, even though they can't survive without it. If they don't get it, then as I said, the course of the disease proves fatal. When it comes to someone with MVID, a delay in diagnosis at birth means death. Should they receive a diagnosis, they'll be placed on Total Parenteral Nutrition right from birth, and usually they won't make it past their teen years — mainly due to the intravenous procedures, which bring infections and various other complications. However, TPN causes serious harm to the kidneys, the liver, and cognitive function, and patients frequently follow a far slower growth trajectory. So what endpoint are we seeking in our trials? What are we aiming for when crofelemer is the intervention? Even a 5% decrease in TPN and parenteral support would count as meaningful. I spoke with a patient advocate only two weeks back. Why does that matter? Because cutting the duration a patient spends on parenteral support by even 10% or 15% could, for instance, let a child stop receiving IV nutrition and return to school. While they're sleeping, they're able to receive nearly all—or perhaps every bit—of the parenteral support they require. That changes things enormously for the patient, and also for everyone around them: the doctor, frequently nurses, dietitians, and loved ones, all coordinating their efforts. Remember, these individuals require parenteral nutrition on a daily basis. So the encouraging results we've achieved up to now in the intestinal-failure space came out of a standalone proof-of-concept study that tested crofelemer in pediatric patients over in the UAE. Those children had intestinal failure — one case stemming from microvillus inclusion disease and two from short bowel syndrome — and the findings were shared on November 8 of last year, 2025, at NASPGHAN, which stands for the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition. The presentation was given by the study's primary investigator, Dr. Mohammed Miqdady, who has worked alongside the Company as a colleague and collaborator for a long stretch — about 8 years at this point. First, let me highlight what we found. Crofelemer appears to modify how the disease progresses by cutting down the need for parenteral support. That's the primary endpoint I brought up earlier for pediatric intestinal failure patients, and the decrease fell somewhere between 12% and 37%. Keep in mind what I said before — a drop of just 5% would already count as meaningful. And when I talk about meaningful, I'm referring to how regulatory bodies like the FDA view it. To get specific: among the 2 pediatric short bowel syndrome intestinal failure patients who finished the treatment, the data indicate that crofelemer lowered parenteral support by somewhere in the range of 12.5% to 15.6%.
When it comes to the MVID patient, the need for parenteral support went down by as much as 37%, and we haven't seen any safety problems. That matches what we know about crofelemer's safety profile, shown across thousands of patients in published clinical trials — in other conditions, plus years of the drug being commercially available at the FDA — as Mytesi, which the FDA approved for the HIV indication. Our expectation is that patients in the ongoing UAE trial will receive crofelemer for the remainder of their lives; right now, at this point, these patients have been on treatment for more than a year. At the start, under the investigator-initiated trial protocol, they received treatment for roughly 3 months with escalating doses. And then, once again, with no safety problems, they came off the drug, and extremely, extremely fast, within literally days. The community, and the treating community, the parents and the physicians, all immediately felt the need to get the patients back on treatment because a relapse situation had developed, and that's a highly important sign of benefit when you're in a situation without a placebo control; so, with FDA backing for a recently submitted protocol amendment for our placebo-controlled trial, which is fully enrolled for MVID, we'll keep evaluating crofelemer's safety and efficacy. Now, this is crofelemer, but in terms of formulation, it isn't Mytesi. It's a highly concentrated liquid formulation suited to intestinal failure patients, since, as you can imagine, a pill would pass straight through them, and we're also discussing pediatric patients, in some cases infants, being given this product. In this trial, which, as I said, is fully enrolled, the placebo-controlled trial, we filed an amendment to create the opportunity for patients to move into a treatment-only extension phase; and once again, the expectation is that we would supply product for the remainder of their lives; and this trial is running, as often happens with rare diseases, globally, so you can reach the patients; so, in the United States, in Italy, and in the UAE. We're discussing an opportunity to finish our regulatory program and potentially file, with continued response as we're seeing, for a New Drug Application based on a single-digit number of patients. We also expect to be able to file for a Breakthrough designation from — with the FDA, which is an opportunity to speed up the U.S. regulatory path and potentially qualify for the European Medicines Agency, which is like the FDA of Europe, PRIME priority medicines, which can accelerate the regulatory path to approval and to market and commercialize and provide patient access in all 27 EU countries. As I said, the target for the NDA with the FDA, the New Drug Application, is in the first half of 2027, MVIC against a devastating, catastrophic, ultra-rare pediatric disorder; the estimated worldwide prevalence is about 200 patients. So this crofelemer trial, involving only a modest patient count, ought to deliver results that carry statistical weight and real-world significance, making a tremendous difference for each person enrolled and lending support to a registration filing. No treatments exist, not even ones under clinical study, for MVID apart from parenteral support that keeps patients alive — and again, the natural course of this disease is fatal, which highlights how badly new options are needed. We hold Orphan Designation across the U.S. and Europe covering MVID as well as short bowel syndrome. That status delivers not just the chance to work with fewer participants — and by the way, at considerably reduced expense, with fewer subjects needed in trials — but also substantial regulatory leverage and dialogue as we move the program forward, and we have certainly been capitalizing on that. As I noted, by coincidence in timing, we also have the intestinal-failure program strengthened by clinical proof-of-concept data gathered in pediatric patients whose intestinal failure stems from short bowel syndrome. An ongoing randomized, double-blind, placebo-controlled Phase II study is underway — once more, testing this highly concentrated liquid formulation of crofelemer — in adults with short bowel syndrome intestinal failure. Short bowel syndrome and intestinal failure impact a patient population much bigger than MVID, even though it remains an orphan indication. This condition originates from congenital anomalies, surgical resection tied to Crohn's disease, cancer, accidents. Adults and children dealing with intestinal failure endure chronic reliance on parenteral support because their intestine lacks sufficient absorptive surface area; therefore, in contrast to MVID, where the patient's intestine remains completely intact yet fails to function, the intestinal-failure picture in short bowel syndrome patients results from their shortened bowel. A normal intestine for us is generally 20, 25 feet; these may measure 5 feet or fewer; thus there simply isn't enough geography to take in life's nutrients. The patient population was estimated at roughly 12,000 patients across the United States in 2021, based on a third-party epidemiology study. We anticipate that approval of crofelemer for MVID would bolster the development program for SBS-IF, since an MVID approval would probably draw additional partnering interest, given that it's the identical product. It's a separate indication, yet it would be the same product, safety, manufacturing. We get to gain from the approval already existing for Mytesi for crofelemer, albeit in another formulation, and then the efficacy. To be very specific, we're seeking a partner to help fund the final development and commercialization of crofelemer for MVID and short bowel syndrome IF, with the partner handling commercialization outside the United States, serving the global need of this population. Drugs are, naturally, approved on the basis of manufacturing and safety, which I referenced. Once again, we get to leverage what's already established plus the efficacy, safety, the benefit-risk ratio, with a risk of 0, the benefit — whatever benefit we can demonstrate, and keep demonstrating from our proof-of-concept data, can be infinity and beyond. We showed we can get things done and finalize major non-dilutive agreements, starting back in January when I opened this presentation with the Future Pak transaction. To repeat, $16 million in non-dilutive funds came in upfront during January, with another $2 million still to arrive, and $20 million potentially over the life of the arrangement, of which more than $3 million in other funds has already come our way in this market. The IF market is viewed as 100x bigger than the HIV market. Given the clinical proof-of-concept results we currently hold, plus near-term clinical and regulatory milestones in progress from investigator-initiated trials, from presentations and publications, from the placebo-controlled studies we are running, and with patients moving into the treatment-only extension phase, we feel confident in our capacity and our commitment to deliver on our Business Development objectives and strategy for our IF program, and to create further chances to bring in additional non-dilutive funds. I will now pass things to Carol so she can walk through the financial highlights we issued earlier this week for the third quarter of 2025. The floor is yours, Carol.
Okay, good morning, Lisa, and thanks to everyone for tuning in to our webcast today. I want to kick off with my review of the financials for Q4 of 2025. Net revenue on a total basis — covering the Company's prescription items, Mytesi, Gelclair, and Canalevia-CA1, plus the nonprescription products and license revenue — came in at roughly $3.2 million for the fourth quarter of 2025. That marks a rise of 5% compared with total net revenue in Q3 of 2025, which was about $3.1 million, and a drop of roughly 8% versus total net revenue in Q4 of 2024, which came to about $3.5 million. During 2025, sales of Mytesi and Canalevia-CA1 accounted for about $11.2 million of the Company's total net revenue of $11.5 million. Per the license agreement Jaguar struck with Future Pak in January 2026, Future Pak takes on every commercial effort and gets all proceeds from U.S. sales of Mytesi and Canalevia-CA1 starting January 12, 2026. Jaguar's role is supplying product at a premium price and booking manufacturing revenue. Beyond the $16 million upfront license fee and a $3 million payment, Future Pak has already bought product from Jaguar. Last month we told you that the $3 million payment came before Jaguar ended the buy-back provision of the Licensing Agreement we signed with Future Pak in January. That lets Future Pak keep commercializing Mytesi past 5 years. As Lisa noted, Jaguar will go on manufacturing Mytesi and Canalevia-CA1 for Future Pak, and this Licensing Agreement fits with Jaguar's strategy of focusing on crofelemer late-stage development work for human rare-disease intestinal failure indications. Mytesi prescription volume fell about 3.7% in 2025 compared with 2024, about 5.8% in Q4 of 2025 compared with Q3 of 2025, and about 12.2% in Q4 of 2025 compared with the same period a year earlier. Prescription volume isn't the same as invoiced sales volume, which reflects, among other things, differing buying patterns among specialty pharmacies within the closed-network as they handle their inventory levels. Loss from operations grew by $15.1 million, going from $30.8 million for the year ended December 31, 2024, to $45.9 million in 2025. Non-GAAP Recurring EBITDA for 2025 and 2024 came to net losses of $48.1 million and $35.9 million, respectively. Net loss attributable to common shareholders rose by roughly $15.1 million, from $38.5 million for the year ended December 31, 2024, to $53.6 million in 2025. Apart from the loss from operations, the fair value of financial and hybrid instrument designation at Fair Value Option declined by $3.2 million, moving from a loss of $9.5 million for the year ended December 31, 2024, to a loss of $6.3 million in 2025, largely because of fair value adjustments in notes-payable designated at FVO or Fair Value Option. Debt extinguishment moved from a $1.2 million gain for the year ended December 31, 2024, to a $1.8 million loss in 2025 — a $3 million increase — mainly because of significant changes to the projected payments under one royalty-interest agreement, which brought about extinguishment accounting. That wraps up my overview of the high-level financials through the fourth quarter of 2025, and I'll now turn things back over to Lisa.
Thank you so much, Carol. And I appreciate all of you joining us. I should note that although the Future Pak transaction delivers, as I mentioned, capital that isn't dilutive along with worth to support our rare-disease initiative — the benefit to Future Pak matters a great deal when it comes to HIV, specifically adding Mytesi into what they offer. In the prior year, Future Pak acquired Theratechnologies, a company with 2 HIV programs — correction, 2 HIV products — and there's striking alignment in the targets and in the doctors caring for patients likely dealing with GI issues and diarrhea tied to HIV; these tend to be older individuals, roughly 50% of those living with HIV in the United States today are beyond age 50 and have carried the virus in their gut for more than 10 years, frequently facing enteropathy along with the inflammation that may produce leaky gut and diarrhea. And they — so they bring a track record, an existing product lineup, and far stronger commercialization reach than Jaguar possesses. That means Mytesi is well positioned to reach those patients facing an unmet medical need, and it frees us to concentrate on our upcoming indications with substantial unmet medical need and disease that, again, carries a lethal natural history; hence the chance to help with immediate symptom relief, modification of disease progression, and possibly extending how long the patient lives. All right. We anticipate sharing clinical proof-of-concept milestones and Business Development conversations across the remainder of this year and on into 2027, with a very clear objective and emphasis on securing non-dilutive funding from a potential licensing partner or partners; all of us at Jaguar, Napo, and Napo Therapeutics stay completely energized and enthusiastic about the many expected near-term catalysts for crofelemer and the Company, every one of which we regard as meaningful, value-enhancing, and potentially transformative for patients, for the Company, and for everyone with a stake in it. Have a good day. That wraps up our webcast for today, and we'll see you with the next quarter.
Thanks. That wraps up the conference call for today, everyone. You can go ahead and hang up now. We appreciate you joining us.
For developers and AI pipelines
Programmatic access to Jaguar Health, Inc. earnings transcripts and 132,000+ others is available through the
EarningsAPI REST API and the hosted MCP server.
Quarterly plans from $162 - full transcripts, speaker segments, full-text search,
and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.